Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
University of California, Los Angeles · Memorial Sloan Kettering Cancer Center · +7 more institutions
Abstract
Abstract We explored the association between liver metastases, tumor CD8+ T-cell count, and response in patients with melanoma or lung cancer treated with the anti-PD-1 antibody, pembrolizumab. The melanoma discovery cohort was drawn from the phase I Keynote 001 trial, whereas the melanoma validation cohort was drawn from Keynote 002, 006, and EAP trials and the non–small cell lung cancer (NSCLC) cohort from Keynote 001. Liver metastasis was associated with reduced response and shortened progression-free survival [PFS; objective response rate (ORR), 30.6%; median PFS, 5.1 months] compared with patients without liver metastasis (ORR, 56.3%; median PFS, 20.1 months) P ≤ 0.0001, and confirmed in the validation…
Citation impact
- FWCI
- 18.53
- Percentile
- 100%
- References
- 43
Authors
34- PCPaul C. Tumeh
University of California, Los Angeles
- MDMatthew D. Hellmann
Memorial Sloan Kettering Cancer Center, Kettering University
- OHOmid Hamid
Angeles Clinic and Research Institute
- KKKaty K. Tsai
University of California, San Francisco, University of San Francisco
- KLKimberly Loo
University of California, San Francisco, University of San Francisco
Topics & keywords
- Medicine
- Monoclonal antibody
- Melanoma
- Metastasis
- Immunotherapy
- Antibody
- Oncology
- Cancer research
- Good health and well-being